 | • レポートコード：MRC2312A088 • 出版社/出版日：Transparency Market Research / 2023年8月24日 • レポート形態：英文、PDF、284ページ • 納品方法：Eメール • 産業分類：バイオ |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 細胞・遺伝子療法製造市場 - レポートの範囲TMRの調査レポート「世界の細胞・遺伝子療法製造市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の細胞・遺伝子療法製造市場の収益を提供しています。また、2023年から2031年までの世界の細胞・遺伝子療法製造市場の複合年間成長率（CAGR %）も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、細胞・遺伝子療法製造市場を理解しました。 二次調査には、インターネットソース、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストはトップダウンアプローチとボトムアップアプローチを組み合わせて、世界の細胞・遺伝子療法製造市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは世界の細胞・遺伝子療法製造市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界の細胞・遺伝子療法製造市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートでは、世界の細胞・遺伝子療法製造市場の競争状況について掘り下げています。世界の細胞・遺伝子療法製造市場で事業を展開する主要プレイヤーを特定し、各プレイヤーを様々な属性でプロファイルしています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の細胞・遺伝子療法製造市場におけるプレイヤーの属性です。 世界の細胞・遺伝子療法製造市場レポートで回答された主な質問 - 予測期間中の全地域における細胞・遺伝子療法製造の売上高/収益は？ - 世界の細胞・遺伝子療法製造市場におけるビジネスチャンスは？ - 市場の主な促進要因、阻害要因、機会、脅威は？ - 予測期間中に最も速いCAGRで拡大する地域市場は？ - 2031年に世界で最も高い収益を上げると予測されるセグメントは？ - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは？ - 世界市場で事業を展開する各企業の市場ポジションは？ 細胞・遺伝子療法製造市場 - 調査目的と調査アプローチ 世界の細胞・遺伝子療法製造市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフと表を適切に配置した網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化することで、読者に視覚的に訴えかけます。また、主要セグメントの過去と予測期間末の市場シェアの比較も可能です。 本レポートでは、世界の細胞・遺伝子療法製造市場を製品、エンドユーザー、地域の観点から分析。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界細胞・遺伝子療法製造市場への投資について十分な情報に基づいたビジネス上の意思決定を行うことができます。 |
1. 序論
2. 仮定・調査方法
3. エグゼクティブサマリー：細胞・遺伝子療法製造市場
4. 市場概要
5. 主要インサイト
6. 世界の細胞・遺伝子療法製造市場分析・予測：治療種類別
7. 世界の細胞・遺伝子療法製造市場分析・予測：製品種類別
8. 世界の細胞・遺伝子療法製造市場分析・予測：技術別
9. 世界の細胞・遺伝子療法製造市場分析・予測：疾患別
10. 世界の細胞・遺伝子療法製造市場分析・予測：エンドユーザー別
11. 世界の細胞・遺伝子療法製造市場分析・予測：地域別
12. 北米の細胞・遺伝子療法製造市場分析・予測
13. ヨーロッパの細胞・遺伝子療法製造市場分析・予測
14. アジア太平洋の細胞・遺伝子療法製造市場分析・予測
15. 中南米の細胞・遺伝子療法製造市場分析・予測
16. 中東・アフリカの細胞・遺伝子療法製造市場分析・予測
17. 競争状況
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Cell and Gene Therapy Manufacturing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Reimbursement Scenario by Region/Globally
5.3. Regulatory Scenario by Region/globally
5.4. Disease Prevalence & Incidence Rate Globally With Key Countries
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2017-2031
6.3.1. Cell Therapy
6.3.1.1. Allogeneic
6.3.1.1.1. Mesenchymal Stem Cells
6.3.1.1.2. T-cells
6.3.1.1.3. Induced Pluripotent Stem Cells
6.3.1.1.4. Natural Killer Cells
6.3.1.1.5. Hematopoietic Stem Cells
6.3.1.1.6. Others
6.3.1.2. Autologous
6.3.1.2.1. T-cells
6.3.1.2.2. Hematopoietic Stem Cells
6.3.1.2.3. Mesenchymal Stem Cells
6.3.1.2.4. Natural Killer Cells
6.3.1.2.5. Others
6.3.2. Gene Therapy
6.3.2.1. Viral Vector
6.3.2.1.1. Lentiviral Vector
6.3.2.1.2. Adeno-associated Virus Vectors
6.3.2.1.3. Other Viral Vectors
6.3.2.2. Non-viral Vector
6.3.2.2.1. Electroporation
6.3.2.2.2. Other Non-viral Vectors
6.4. Market Attractiveness Analysis, by Therapy Type
7. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Product Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Product Type, 2017-2031
7.3.1. Consumables
7.3.2. Equipment
7.3.2.1. Cell Processing Equipment
7.3.2.2. Single-use Equipment
7.3.2.3. Other Equipment
7.3.3. Software & Systems
7.4. Market Attractiveness Analysis, by Product Type
8. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Technology
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. Cell Culture & Expansion
8.3.2. Viral Vector Production
8.3.3. Cell Sorting & Purification
8.3.4. Gene Editing
8.3.5. Others
8.4. Market Attractiveness Analysis, by Technology
9. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Indication, 2017-2031
9.3.1. Oncology Disease
9.3.2. Cardiovascular Disease
9.3.3. Orthopedic Disease
9.3.4. Infectious Disease
9.3.5. Others
9.4. Market Attractiveness Analysis, by Indication
10. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017-2031
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Contract Manufacturing Organizations (CMOs)
10.4. Market Attractiveness Analysis, by End-user
11. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017-2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Cell and Gene Therapy Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017-2031
12.2.1. Cell Therapy
12.2.1.1. Allogeneic
12.2.1.1.1. Mesenchymal Stem Cells
12.2.1.1.2. T-cells
12.2.1.1.3. Induced Pluripotent Stem Cells
12.2.1.1.4. Natural Killer Cells
12.2.1.1.5. Hematopoietic Stem Cells
12.2.1.1.6. Others
12.2.1.2. Autologous
12.2.1.2.1. T-cells
12.2.1.2.2. Hematopoietic Stem Cells
12.2.1.2.3. Mesenchymal Stem Cells
12.2.1.2.4. Natural Killer Cells
12.2.1.2.5. Others
12.2.2. Gene Therapy
12.2.2.1. Viral Vector
12.2.2.1.1. Lentiviral Vector
12.2.2.1.2. Adeno-associated Virus Vectors
12.2.2.1.3. Other Viral Vectors
12.2.2.2. Non-viral Vector
12.2.2.2.1. Electroporation
12.2.2.2.2. Other Non-viral Vectors
12.3. Market Value Forecast, by Product Type, 2017-2031
12.3.1. Consumables
12.3.2. Equipment
12.3.2.1. Cell Processing Equipment
12.3.2.2. Single-use Equipment
12.3.2.3. Other Equipment
12.3.3. Software & Systems
12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. Cell Culture & Expansion
12.4.2. Viral Vector Production
12.4.3. Cell Sorting & Purification
12.4.4. Gene Editing
12.4.5. Others
12.5. Market Value Forecast, by Indication, 2017-2031
12.5.1. Oncology Disease
12.5.2. Cardiovascular Disease
12.5.3. Orthopedic Disease
12.5.4. Infectious Disease
12.5.5. Others
12.6. Market Value Forecast, by End-user, 2017-2031
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Contract Manufacturing Organizations (CMOs)
12.7. Market Value Forecast, by Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Therapy Type
12.8.2. By Product Type
12.8.3. By Technology
12.8.4. By Indication
12.8.5. By End-user
12.8.6. By Country
13. Europe Cell and Gene Therapy Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017-2031
13.2.1. Cell Therapy
13.2.1.1. Allogeneic
13.2.1.1.1. Mesenchymal Stem Cells
13.2.1.1.2. T-cells
13.2.1.1.3. Induced Pluripotent Stem Cells
13.2.1.1.4. Natural Killer Cells
13.2.1.1.5. Hematopoietic Stem Cells
13.2.1.1.6. Others
13.2.1.2. Autologous
13.2.1.2.1. T-cells
13.2.1.2.2. Hematopoietic Stem Cells
13.2.1.2.3. Mesenchymal Stem Cells
13.2.1.2.4. Natural Killer Cells
13.2.1.2.5. Others
13.2.2. Gene Therapy
13.2.2.1. Viral Vector
13.2.2.1.1. Lentiviral Vector
13.2.2.1.2. Adeno-associated Virus Vectors
13.2.2.1.3. Other Viral Vectors
13.2.2.2. Non-viral Vector
13.2.2.2.1. Electroporation
13.2.2.2.2. Other Non-viral Vectors
13.3. Market Value Forecast, by Product Type, 2017-2031
13.3.1. Consumables
13.3.2. Equipment
13.3.2.1. Cell Processing Equipment
13.3.2.2. Single-use Equipment
13.3.2.3. Other Equipment
13.3.3. Software & Systems
13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. Cell Culture & Expansion
13.4.2. Viral Vector Production
13.4.3. Cell Sorting & Purification
13.4.4. Gene Editing
13.4.5. Others
13.5. Market Value Forecast, by Indication, 2017-2031
13.5.1. Oncology Disease
13.5.2. Cardiovascular Disease
13.5.3. Orthopedic Disease
13.5.4. Infectious Disease
13.5.5. Others
13.6. Market Value Forecast, by End-user, 2017-2031
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Contract Manufacturing Organizations (CMOs)
13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Therapy Type
13.8.2. By Product Type
13.8.3. By Technology
13.8.4. By Indication
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Cell and Gene Therapy Manufacturing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017-2031
14.2.1. Cell Therapy
14.2.1.1. Allogeneic
14.2.1.1.1. Mesenchymal Stem Cells
14.2.1.1.2. T-cells
14.2.1.1.3. Induced Pluripotent Stem Cells
14.2.1.1.4. Natural Killer Cells
14.2.1.1.5. Hematopoietic Stem Cells
14.2.1.1.6. Others
14.2.1.2. Autologous
14.2.1.2.1. T-cells
14.2.1.2.2. Hematopoietic Stem Cells
14.2.1.2.3. Mesenchymal Stem Cells
14.2.1.2.4. Natural Killer Cells
14.2.1.2.5. Others
14.2.2. Gene Therapy
14.2.2.1. Viral Vector
14.2.2.1.1. Lentiviral Vector
14.2.2.1.2. Adeno-associated Virus Vectors
14.2.2.1.3. Other Viral Vectors
14.2.2.2. Non-viral Vector
14.2.2.2.1. Electroporation
14.2.2.2.2. Other Non-viral Vectors
14.3. Market Value Forecast, by Product Type, 2017-2031
14.3.1. Consumables
14.3.2. Equipment
14.3.2.1. Cell Processing Equipment
14.3.2.2. Single-use Equipment
14.3.2.3. Other Equipment
14.3.3. Software & Systems
14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. Cell Culture & Expansion
14.4.2. Viral Vector Production
14.4.3. Cell Sorting & Purification
14.4.4. Gene Editing
14.4.5. Others
14.5. Market Value Forecast, by Indication, 2017-2031
14.5.1. Oncology Disease
14.5.2. Cardiovascular Disease
14.5.3. Orthopedic Disease
14.5.4. Infectious Disease
14.5.5. Others
14.6. Market Value Forecast, by End-user, 2017-2031
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Contract Manufacturing Organizations (CMOs)
14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Therapy Type
14.8.2. By Product Type
14.8.3. By Technology
14.8.4. By Indication
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Cell and Gene Therapy Manufacturing Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapy Type, 2017-2031
15.2.1. Cell Therapy
15.2.1.1. Allogeneic
15.2.1.1.1. Mesenchymal Stem Cells
15.2.1.1.2. T-cells
15.2.1.1.3. Induced Pluripotent Stem Cells
15.2.1.1.4. Natural Killer Cells
15.2.1.1.5. Hematopoietic Stem Cells
15.2.1.1.6. Others
15.2.1.2. Autologous
15.2.1.2.1. T-cells
15.2.1.2.2. Hematopoietic Stem Cells
15.2.1.2.3. Mesenchymal Stem Cells
15.2.1.2.4. Natural Killer Cells
15.2.1.2.5. Others
15.2.2. Gene Therapy
15.2.2.1. Viral Vector
15.2.2.1.1. Lentiviral Vector
15.2.2.1.2. Adeno-associated Virus Vectors
15.2.2.1.3. Other Viral Vectors
15.2.2.2. Non-viral Vector
15.2.2.2.1. Electroporation
15.2.2.2.2. Other Non-viral Vectors
15.3. Market Value Forecast, by Product Type, 2017-2031
15.3.1. Consumables
15.3.2. Equipment
15.3.2.1. Cell Processing Equipment
15.3.2.2. Single-use Equipment
15.3.2.3. Other Equipment
15.3.3. Software & Systems
15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. Cell Culture & Expansion
15.4.2. Viral Vector Production
15.4.3. Cell Sorting & Purification
15.4.4. Gene Editing
15.4.5. Others
15.5. Market Value Forecast, by Indication, 2017-2031
15.5.1. Oncology Disease
15.5.2. Cardiovascular Disease
15.5.3. Orthopedic Disease
15.5.4. Infectious Disease
15.5.5. Others
15.6. Market Value Forecast, by End-user, 2017-2031
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Contract Manufacturing Organizations (CMOs)
15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Therapy Type
15.8.2. By Product Type
15.8.3. By Technology
15.8.4. By Indication
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Cell and Gene Therapy Manufacturing Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Therapy Type, 2017-2031
16.2.1. Cell Therapy
16.2.1.1. Allogeneic
16.2.1.1.1. Mesenchymal Stem Cells
16.2.1.1.2. T-cells
16.2.1.1.3. Induced Pluripotent Stem Cells
16.2.1.1.4. Natural Killer Cells
16.2.1.1.5. Hematopoietic Stem Cells
16.2.1.1.6. Others
16.2.1.2. Autologous
16.2.1.2.1. T-cells
16.2.1.2.2. Hematopoietic Stem Cells
16.2.1.2.3. Mesenchymal Stem Cells
16.2.1.2.4. Natural Killer Cells
16.2.1.2.5. Others
16.2.2. Gene Therapy
16.2.2.1. Viral Vector
16.2.2.1.1. Lentiviral Vector
16.2.2.1.2. Adeno-associated Virus Vectors
16.2.2.1.3. Other Viral Vectors
16.2.2.2. Non-viral Vector
16.2.2.2.1. Electroporation
16.2.2.2.2. Other Non-viral Vectors
16.3. Market Value Forecast, by Product Type, 2017-2031
16.3.1. Consumables
16.3.2. Equipment
16.3.2.1. Cell Processing Equipment
16.3.2.2. Single-use Equipment
16.3.2.3. Other Equipment
16.3.3. Software & Systems
16.4. Market Value Forecast, by Technology, 2017-2031
16.4.1. Cell Culture & Expansion
16.4.2. Viral Vector Production
16.4.3. Cell Sorting & Purification
16.4.4. Gene Editing
16.4.5. Others
16.5. Market Value Forecast, by Indication, 2017-2031
16.5.1. Oncology Disease
16.5.2. Cardiovascular Disease
16.5.3. Orthopedic Disease
16.5.4. Infectious Disease
16.5.5. Others
16.6. Market Value Forecast, by End-user, 2017-2031
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Contract Manufacturing Organizations (CMOs)
16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Therapy Type
16.8.2. By Product Type
16.8.3. By Technology
16.8.4. By Indication
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Becton, Dickinson and Company
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Bio-Rad Laboratories, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Bio-Techne Corporation
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Danaher Corporation
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. General Electric Company (GE Healthcare)
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Getinge AB
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Lonza Group Ltd.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Merck KGaA
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Sartorius AG (Sartorius Stedim Biotech S.A.)
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Thermo Fisher Scientific Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
17.3.11. MaxCyte
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. Financial Overview
17.3.11.4. SWOT Analysis
17.3.11.5. Strategic Overview
17.3.12. Fresenius Medical Care AG & Co. KGaA
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. Financial Overview
17.3.12.4. SWOT Analysis
17.3.12.5. Strategic Overview